MicroRNA-218 inhibits proliferation and invasion in ovarian cancer by targeting Runx2
MicroRNA-218 (miR-218) has been implicated in the development and progression of multiple cancers. We investigated the role of miR-218 in ovarian cancer progression. We found that miR-218 expression levels were lower in ovarian cancer tissues and cell lines than in adjacent normal tissues or a normal ovarian cell line.miR-218 levels associated with International Federation of Gynecology and Obstetrics (FIGO) stage and lymph node metastasis. Exogenous expression of miR-218 inhibited cell proliferation, colony formation, migration, and invasion in vitro and suppressed tumor growth in a tumor-bearing nude mouse model. Runt-related transcription factor 2 (RUNX2) was identified as a direct functional target of miR-218, and its expression was inversely correlated with miR-218 expression in ovarian cancer tissues. RUNX2 overexpression rescued the suppressive effect of miR-218 on ovarian cancer cell proliferation, colony formation, migration, and invasion. These findings highlight an important role played bymiR-218 in the regulation of cancer growth and metastasis, in part by repressing RUNX2, and revealed the potential of miR-218 as a new therapeutic target inovarian cancer.
| Errataetall: |
RetractionIn: Oncotarget. 2022 Jul 02;13:863. - PMID 35813282 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Oncotarget - 8(2017), 53 vom: 31. Okt., Seite 91530-91541 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Na [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Invasion |
|---|
| Anmerkungen: |
Date Revised 11.07.2022 published: Electronic-eCollection RetractionIn: Oncotarget. 2022 Jul 02;13:863. - PMID 35813282 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.18632/oncotarget.21069 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM27872938X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM27872938X | ||
| 003 | DE-627 | ||
| 005 | 20231225021310.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18632/oncotarget.21069 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0929.xml |
| 035 | |a (DE-627)NLM27872938X | ||
| 035 | |a (NLM)29207663 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Na |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a MicroRNA-218 inhibits proliferation and invasion in ovarian cancer by targeting Runx2 |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 11.07.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a RetractionIn: Oncotarget. 2022 Jul 02;13:863. - PMID 35813282 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a MicroRNA-218 (miR-218) has been implicated in the development and progression of multiple cancers. We investigated the role of miR-218 in ovarian cancer progression. We found that miR-218 expression levels were lower in ovarian cancer tissues and cell lines than in adjacent normal tissues or a normal ovarian cell line.miR-218 levels associated with International Federation of Gynecology and Obstetrics (FIGO) stage and lymph node metastasis. Exogenous expression of miR-218 inhibited cell proliferation, colony formation, migration, and invasion in vitro and suppressed tumor growth in a tumor-bearing nude mouse model. Runt-related transcription factor 2 (RUNX2) was identified as a direct functional target of miR-218, and its expression was inversely correlated with miR-218 expression in ovarian cancer tissues. RUNX2 overexpression rescued the suppressive effect of miR-218 on ovarian cancer cell proliferation, colony formation, migration, and invasion. These findings highlight an important role played bymiR-218 in the regulation of cancer growth and metastasis, in part by repressing RUNX2, and revealed the potential of miR-218 as a new therapeutic target inovarian cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Retracted Publication | |
| 650 | 4 | |a MiR-218 | |
| 650 | 4 | |a RUNX2 | |
| 650 | 4 | |a invasion | |
| 650 | 4 | |a ovarian cancer | |
| 650 | 4 | |a proliferation | |
| 700 | 1 | |a Wang, Lufei |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Guangyun |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Zhiheng |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Ming |e verfasserin |4 aut | |
| 700 | 1 | |a He, Jin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncotarget |d 2010 |g 8(2017), 53 vom: 31. Okt., Seite 91530-91541 |w (DE-627)NLM199620113 |x 1949-2553 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2017 |g number:53 |g day:31 |g month:10 |g pages:91530-91541 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18632/oncotarget.21069 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2017 |e 53 |b 31 |c 10 |h 91530-91541 | ||